NCT04491916

Iron Therapy in Patients With End-Stage Renal Disease

A Cross-over Trial to Evaluate the Efficacy and Safety Between Increasing the Dose of Iron and Original Iron Dosage in Patients With Maintenance Hemodialysis

• Status: Unknown
• Phase: N/A
• Study type: Interventional
• Enrollment: 200 (estimated)
• Sponsor: Kaohsiung Medical University Chung-Ho Memorial Hospital · Academic / Other
• Sex: All
• Age: 20 Years – 99 Years
• Healthy volunteers: Not accepted

Summary

This study will compare the clinical outcome of patients with maintenance dialysis room after changing the iron treatment guidelines from original upper limit with ferritin\>500ng/ml, or TSAT\>20% to Ferritin\> 800ng / ml, or TSAT\> 50%.

Detailed description

After two years of treatments, we will compare the incidence of clinical events, monthly blood, and biochemical examination data for the two years before and after the change.

Conditions

• End-stage Renal Disease
• Anemia
• Cardiovascular Risk Factor
• Inflammation

Interventions

Type	Name	Description
DRUG	irone sucrose	drug ingredient: Ferric Hydroxide in complex with sucrose drug dosage form: 270injection/100mg/5ml/Amp

Timeline

• Start date: 2020-04-01
• Primary completion: 2022-12-31
• Completion: 2022-12-31
• First posted: 2020-07-30
• Last updated: 2020-07-30

Locations

1 site across 1 country: Taiwan